文献速递腹部CT

细胞外容积分数可预测结直肠癌肝转移的治疗反应与生存结局

Extracellular volume fraction can predict the treatment response and survival outcome of colorectal cancer liver metastases.
PubMed 文献 · Eur J Radiol · 2024-03-25

研究纳入186个经病理或随访证实的结直肠癌肝转移病灶,分析化疗联合贝伐珠单抗2周期前后细胞外容积分数变化,按RECIST v1.1于12周期后评估治疗反应。ΔECV为治疗反应的独立预测因子,高CRD_score提示更短的无进展生存期和总生存期。

要点

  • ΔECV是结直肠癌肝转移化疗联合贝伐珠单抗治疗反应的独立预测因子(OR 1.03)。
  • 治疗反应模型在训练集和测试集的AUC分别为0.87和0.84。
  • 高CRD_score提示更短的无进展生存期(HR 2.01)和总生存期(HR 1.89)。

核心结论

  • ΔECV可作为结直肠癌肝转移化疗联合贝伐珠单抗治疗反应的独立预测因子。

研究设计与样本

  • 共纳入186个经病理或随访证实的结直肠癌肝转移病灶,训练集130个、测试集56个;分析化疗联合贝伐珠单抗2周期前后ECV分数的变化,12周期后按RECIST v1.1评估治疗反应;采用多因素logistic回归筛选治疗反应预测因子,COX分析筛选PFS和OS危险因素。

诊断标准与关键数值

  • ΔECV预测治疗反应(TR-)的OR为1.03(95%CI 1.02-1.05,P<0.01)。
  • 治疗反应模型在训练集的AUC为0.87,敏感度90.14%,特异度72.88%。
  • 治疗反应模型在测试集的AUC为0.84,敏感度90.32%,特异度64.00%。
  • ΔECV、ΔHUA-E和纹理可区分训练集和测试集中肝转移病灶的治疗反应(P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the prognostic value of pre- and post-therapeutic changes in extracellular volume (ECV) fraction of liver metastases (LMs) for treatment response (TR) and survival outcomes in colorectal cancer liver metastases (CRLM).

METHODS: 186 LMs were confirmed by pathology or follow-up (Training: 130; Test: 56). We analyzed the changes in ECV fraction of LMs before and after 2 cycles of chemotherapy combined with bevacizumab. After 12 cycles, we evaluated the TR on LMs based on the RECIST v1.1. Relative changes in ECV fraction and Hounsfield Units (HU), defined as ΔECV and ΔHU, were associated with progression-free survival (PFS), overall survival (OS), and TR. We identified TR predictors with multivariate logistic regression and PFS, OS risk factors with COX analysis.

RESULTS: 186 LMs were classified as TR lesions (TR+: 84) and non-TR lesions (TR-:102). ΔECV, ΔHUA-E, and texture could distinguish the TR of LMs in training and test set (P < 0.05). ΔECV [Odds ratio (OR): 1.03; 95% Confidence interval (CI): 1.02-1.05, P < 0.01] was an independent predictor of TR-. Area under the curve (AUC), sensitivity and specificity of TR model in training and test set were 0.87, 0.84, 90.14%, 90.32%, 72.88%, 64.00%, respectively. High CRD_score indicates that patients have shorter PFS [Hazard ratio (HR): 2.01; 95%CI: 1.02-3.98, P = 0.045)] and OS (HR: 1.89, 95%CI: 1.04-3.42, P = 0.038).

CONCLUSION: ΔECV can be used as an independent predictor of TR of CRLM chemotherapy combined with bevacizumab.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Li S, Yang X, Lu T, et al. Extracellular volume fraction can predict the treatment response and survival outcome of colorectal cancer liver metastases. Eur J Radiol. 2024. PMID: 38531223. doi:10.1016/j.ejrad.2024.111444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。